Trial Profile
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea and Vomiting in Cancer Patients
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Netupitant/palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 04 Mar 2022 Status changed from active, no longer recruiting to completed.
- 07 Jan 2022 Planned End Date changed from 30 Nov 2021 to 30 Nov 2022.
- 07 Jan 2022 Planned primary completion date changed from 30 Nov 2021 to 30 Nov 2022.